iShares Biotechnology ETF Newsroom

RBC Cuts Price Target on Biogen to $303 From $317, Keeps Outperform Rating

MT Newswires07:33 ET

Evercore ISI Adjusts Price Target on IQVIA Holdings to $230 From $250, Maintains Outperform Rating

MT Newswires06:57 ET

UBS Keeps Their Hold Rating on Argenx Se (ARGX)

TipRanks04:45 ET

Goldman Sachs Adjusts Price Target on Mettler-Toledo International to $1,300 From $1,150, Maintains Neutral Rating

MT NewswiresJul 8 06:59 ET

Gilead Sciences Analyst Ratings

BenzingaJul 8 05:34 ET

Alnylam Pharmaceuticals Analyst Ratings

BenzingaJul 3 10:51 ET

Buy Rating for Regeneron Pharmaceuticals Amidst EU Approval of Dupixent and Positive Market Outlook

TipRanksJul 3 09:29 ET

Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Natera (NTRA) and Argenx Se (ARGX)

TipRanksJul 3 08:15 ET

JPMorgan Chase Raises Price Target on Alnylam Pharmaceuticals to $248 From $160

MT NewswiresJul 3 06:55 ET

Mettler-Toledo Intl Analyst Ratings

BenzingaJul 2 11:51 ET

Evercore ISI Adjusts Price Target on Mettler-Toledo International to $1,390 From $1,375, Maintains In-line Rating

MT NewswiresJul 2 07:59 ET

Buy Rating Affirmed for Argenx Se on Strong Vyvgart Uptake and Promising Revenue Projections

TipRanksJul 2 07:03 ET

Alnylam Pharmaceuticals Analyst Ratings

BenzingaJul 1 10:10 ET

Gilead Sciences Analyst Ratings

BenzingaJul 1 10:01 ET

Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $150 Price Target

BenzingaJul 1 08:50 ET

Wedbush Sticks to Their Buy Rating for Argenx Se (ARGX)

TipRanksJul 1 08:37 ET

Argenx Analyst Ratings

BenzingaJul 1 08:34 ET

Gilead Sciences (GILD) Receives a Hold From RBC Capital

TipRanksJul 1 06:37 ET

IQVIA Hldgs Analyst Ratings

BenzingaJun 28 11:51 ET

Amgen Analyst Ratings

BenzingaJun 27 13:48 ET